Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Caligan Partners LP

Q2 2023 · 13F-HR

Caligan Partners LPholdings as filed

Filed 2023-08-14 · accession 0001727492-23-000009

$177.8M
Reported value
13
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
53635D202LQDALIQUIDIA CORP$72.6M40.8%9,243,627CommonSOLE
035255108ANIKANIKA THERAPEUTICS INC$18.7M10.5%720,291CommonSOLE
30161Q104EXELEXELIXIS INC$17.4M9.79%910,730CommonSOLE
34385P108LABSTANDARD BIOTOOLS INC$16.3M9.19%8,467,920CommonSOLE
45845P108INTERCEPT PHARMACEUTICALS INC$14.3M8.05%1,293,510CommonSOLE
45845P958INTERCEPT PHARMACEUTICALS INC$13.3M7.46%1,200,000PUTSOLE
30052C107EOLSEVOLUS INC$12.8M7.20%1,760,136CommonSOLE
925050106VRNAVERONA PHARMA PLC$3.9M2.18%183,064CommonSOLE
000899104ADMAADMA BIOLOGICS INC$3.1M1.76%847,513CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$2.7M1.52%310,298CommonSOLE
016259202ALIMERA SCIENCES INC$1.4M0.79%478,777CommonSOLE
75629F109RAHSOCIETAL CDMO INC$1.2M0.67%1,077,268CommonSOLE
00847X104AGIOAGIOS PHARMACEUTICALS INC$136,8710.08%4,833CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.